Lightspeed Venture Partners, a global venture capital firm, led a $300m funding round in Orca Bio, a clinical-stage biotechnology company, with participation from 8VC, DCVC Bio, ND Capital, Mubadala Investment Company, Kaiser Permanente Group Trust and IMRF. “Orca Bio’s visionary leadership team, seasoned advisors, solid financial foundation and novel technology make the company uniquely suited to develop truly differentiated, scalable allogeneic cell therapies. I look forward to the Orca Bio team’s continued development and commercialization of revolutionary allogeneic cell therapies,” Jonathan MacQuitty, Lightspeed Venture Partners Partner.